StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
KMCSHIL.BO$115.00+3.88%
Fair $115.00+0.0%

KMCSHIL.BO

KMC Speciality Hospitals (India) Limited

Healthcare / Medical Care FacilitiesBSE

$115.00

+3.75 (+3.88%)

Fairly Valued+0.0%Fair Value $115.00Fund rank 24/100 · Data gapFallback financials|
SA 58/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-63.0M · quality 39.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 10/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

58/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · KMCSHIL.BOLocal privado en este navegador · KMC Speciality Hospitals (India) Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$18.8B

P/E

51.3x

↑

EV/EBITDA

20.5x

↑

ROE

22.2%

↑

Gross Margin

85.3%

↑

Debt/Equity

0.40

↑
52-Week Range$115
$63$104

TradingView lightweight chart

KMCSHIL.BO price, volumen y niveles de valoración

Último $100.52Periodo +34.4%
Fair value: $115.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+25.4%

FCF CAGR

—

FCF margin

20.4%

FCF / Net income

1.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.06B · net income $467.3M · FCF $624.6M

2023-FY → 2026-FY

Gross margin

85.3%+0.1% pts

Operating margin

21.7%-0.6% pts

Net margin

15.3%-1.9% pts

FCF margin

20.4%+28.0% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$3.06B$3.06B$2.32B$1.75B$1.55B
Net Income$467.3M$467.3M$214.3M$303.8M$266.9M
EBITDA$930.0M$930.0M$599.7M$509.5M$444.4M
EPS——1.311.861.64
Gross Margin85.3%85.3%85.5%86.1%85.2%
Operating Margin21.7%21.7%16.4%21.8%22.2%
Net Margin15.3%15.3%9.3%17.3%17.2%
Balance Sheet
Debt/Equity0.400.400.540.570.44
Current Ratio1.901.90———
Cash Flow
Free Cash Flow$624.6M$624.6M$-63.0M$-368.5M$-117.9M
Returns
ROE22.2%22.2%13.0%21.2%23.5%
Valuation
P/E51.3451.3449.69——
EV/EBITDA20.5320.5319.09——
P/B8.918.916.48——
Growth & Yield
Revenue Growth32.0%32.0%32.0%13.3%—
EPS Growth——-29.6%13.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +46.2%

Total return

+46.2%

Start / end P/E

n/dx → n/dx

EPS bridge

1.31 → n/d

Residual

+46.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+46.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.